ライフサイエンスコーパス: gammopathy

1 s a rare disorder associated with monoclonal gammopathy.

2 ry amyloidosis with a concomitant monoclonal gammopathy.

3 marrow and the presence of an IgM monoclonal gammopathy.

4 racutaneous manifestations, and a monoclonal gammopathy.

5 me (FS) is a rare complication of monoclonal gammopathy.

6 era of individuals with a form of monoclonal gammopathy.

7 ge, 42-80 years) of the IBM patients without gammopathy.

8 ogy in patients who do not have a monoclonal gammopathy.

9 of patients will have persistent monoclonal gammopathy.

10 al reorganization of AL and other monoclonal gammopathies.

11 amate than patients with indolent monoclonal gammopathies.

12 ) cells across the progression of monoclonal gammopathies.

13 implicated in the pathogenesis of monoclonal gammopathies.

14 ed gammopathies and some sporadic monoclonal gammopathies.

15 disease have an increased risk of monoclonal gammopathies.

16 replication in the persistence of monoclonal gammopathy.1 It has been known for some time that patien

17 nts (91.9%) with monoclonal immunoglobulin G gammopathy, 20 (58.8%) had kappa light chains.

18 multiple myeloma (8% vs. 0), and monoclonal gammopathy (22% vs. 16%).

19 ropoietin and erythrocytosis; (3) monoclonal gammopathy; (4) perinephric fluid collections; and (5) i

20 Further investigation revealed a monoclonal gammopathy, a unique patterning of subcutaneous fat reti

21 rized by urticarial exanthema and monoclonal gammopathy accompanied by systemic symptoms such as feve

22 ) are preceded by an asymptomatic monoclonal gammopathy (AMG), classified as either monoclonal gammop

23 y underlie both Gaucher's disease-associated gammopathies and some sporadic monoclonal gammopathies.

24 symptomatic patients) had both a monoclonal gammopathy and a hereditary variant.

25 alignancy characterized by an IgM monoclonal gammopathy and bone marrow (BM) infiltration with lympho

26 e always preceded by a detectable monoclonal gammopathy and by elevated biomarkers of organ involveme

27 (21%) patients were positive for monoclonal gammopathy and had a faster rate of recurrence and graft

28 ew the causal association between monoclonal gammopathy and neuropathy, and critically review the rec

29 unknown, but in many patients the monoclonal gammopathy and other B-cell abnormalities can be reverse

30 on have an increased incidence of monoclonal gammopathy and plasma cell dyscrasias.2,3 The exact mech

31 a causal relationship between the monoclonal gammopathy and the renal damage and because the signific

32 ambda J lambda rearrangements in lambda-type gammopathies, and that of other Abs to thymus-dependent

33 ogic workup revealed an IgG kappa monoclonal gammopathy, and bone marrow biopsy confirmed smoldering

34 cterized by an urticarial rash, a monoclonal gammopathy, and clinical, histological, and biological s

35 with C3G had GN unrelated to the monoclonal gammopathy, and one with PGNMID did not complete the fir

36 hy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome is a rare

37 current urticarial rash and a monoclonal IgM gammopathy, and two of the following minor criteria: rec

38 ey diseases associated with other monoclonal gammopathies are being recognized.

39 Monoclonal gammopathies are frequently complicated by kidney lesion

40 The IgG and IgA monoclonal gammopathies are rarely associated with specific neuropa

41 IgD monoclonal gammopathies are uncommon.

42 (MGUS) is the most commonly found monoclonal gammopathy associated with neuropathy.

43 by recurrent urticarial rash and monoclonal gammopathy, associated with clinical and biological sign

44 Clarkson disease [monoclonal gammopathy-associated idiopathic systemic capillary leak

45 Clarkson disease, or monoclonal gammopathy-associated idiopathic systemic capillary leak

46 ofluorescence in the diagnosis of monoclonal gammopathy-associated kidney diseases.

47 sis with precision therapy in the monoclonal gammopathy-associated kidney disorders.

48 group of patients with ISCLS have monoclonal gammopathy-associated SCLS (also known as Clarkson disea

49 rgan involvement in patients with monoclonal gammopathies at higher risk to develop the disease.

50 stics of human disease, including monoclonal gammopathy, BM infiltration with lytic bone lesions, and

51 In patients with monoclonal gammopathies, C-reactive protein may be a more specific

52 2% of age-matched controls, had a monoclonal gammopathy characterized as IgG lambda in 9 patients, Ig

53 (MIDD) is a rare complication of monoclonal gammopathy characterized by deposition of monoclonal Ig

54 ain human sera from patients with monoclonal gammopathies contain factors that induce myelin repair i

55 t results led us to consider that monoclonal gammopathy could be the cause of this entity.

56 In patients with monoclonal IgG gammopathies, diagnosis is definite if three minor crite

57 ion in the immunoglobulin M (IgM) monoclonal gammopathy disease spectrum remains poorly understood.

58 In conclusion, FS associated with monoclonal gammopathy does not appear to confer an additional risk

59 in 305 patients with asymptomatic monoclonal gammopathy enrolled in S0120 under the auspices of SWOG.

60 ical and laboratory findings with monoclonal gammopathy evaluation and, if indicated, TTR gene testin

61 an screen subjects who have known monoclonal gammopathy for amyloid organ dysfunction and damage, all

62 pheral neuropathy associated with monoclonal gammopathies has been advanced by recent clinical studie

63 t not nonprogressive myeloma or premalignant gammopathy, have a marked deficiency of ligand-dependent

64 iated skeletal destruction, serum monoclonal gammopathy, immune suppression, and end-organ sequelae.

65 Ophthalmologists should consider monoclonal gammopathies in unexplained bilateral interstitial kerat

66 emia/small lymphocytic lymphoma), monoclonal gammopathy in 20%, and multiple myeloma in 6%.

67 tor in child GP patients and with monoclonal gammopathy in adult GP patients, who frequently showed I

68 The high frequency of monoclonal gammopathy in adult patients with C3 glomerulopathy (C3G

69 ion ameliorates Gaucher's disease-associated gammopathy in mice.

70 rasias.2,3 The exact mechanism of monoclonal gammopathy in patients with HIV infection is unknown, bu

71 Monoclonal gammopathy in several patients may have potential clinic

72 lification was detected in 67% of monoclonal gammopathies, including monoclonal gammopathy of undeter

73 globulin in 33% of sporadic human monoclonal gammopathies is also specific for the lysolipids LGL1 an

74 ical progression in patients with monoclonal gammopathies is associated with an acquired but potentia

75 l disease, the persistence of the monoclonal gammopathy is associated with high rates of recurrence a

76 d because the significance of the monoclonal gammopathy is no longer undetermined.

77 mouse models of Gaucher's disease-associated gammopathy is reactive against lyso-glucosylceramide (LG

78 ears before diagnosis to detect a monoclonal gammopathy (M-Ig).

79 All patients had serum monoclonal IgM gammopathy (median, 2.6 g/L; range, 0.1-40 g/L).

80 ing and serum electrophoresis for monoclonal gammopathy (MG or M-protein).

81 on, the presence of non-malignant monoclonal gammopathy (MG) can be causally associated with kidney d

82 A high prevalence of monoclonal gammopathy (MG) has been observed in HIV-infected patien

83 predictors of finding lesions of monoclonal gammopathy (MG) of renal significance (MGRS) on kidney b

84 s that is usually associated with monoclonal gammopathy (MG).

85 with chronic kidney disease with monoclonal gammopathy (MG).

86 Detection of light chain (LC) monoclonal gammopathies (MGs) traditionally relies on serum free LC

87 ls compared with the marrow in preneoplastic gammopathy (monoclonal gammopathy of undetermined signif

88 ere we show that patients with preneoplastic gammopathy mount a vigorous T cell response to autologou

89 tudies might seek to identify, with biclonal gammopathy multiple myeloma as an investigative model, t

90 study, we identified patients with biclonal gammopathy multiple myeloma by central laboratory analys

91 Biclonal gammopathy multiple myeloma is characterised by the coex

92 44 patients with biclonal gammopathy multiple myeloma with IgG or IgA MGUS clones

93 results show that, in patients with biclonal gammopathy multiple myeloma, anti-multiple myeloma thera

94 py in patients newly diagnosed with biclonal gammopathy multiple myeloma.

95 d tumor bed in 23 patients with premalignant gammopathy, nonprogressive myeloma, or progressive multi

96 only 15% of patients, included 21 monoclonal gammopathies of renal significance; 15 multiple myelomas

97 bone marrow trephine samples from monoclonal gammopathies of undetermined significance (MGUS) and fro

98 paraprotein target (paratargs) in monoclonal gammopathies of undetermined significance (MGUS), multip

99 n can be identified as in myeloma/monoclonal gammopathies of undetermined significance (MGUS).

100 tients (29 AL, 23 MM, and 9 MGUS [monoclonal gammopathies of undetermined significance]) were studied

101 light-chain (AL) amyloidosis, and monoclonal gammopathy of clinical significance (MGCS), all of which

102 It focuses on the concept of monoclonal gammopathy of clinical significance, which can have a la

103 OMAD to be included in neurologic monoclonal gammopathy of clinical significance.

104 M-protein concentrations at the monoclonal gammopathy of indeterminate potential (MGIP) level were

105 Given the propensity for monoclonal gammopathy of macular significance to transform into mal

106 tive disorder that we have termed monoclonal gammopathy of macular significance.

107 und in 89% of patients, including monoclonal gammopathy of renal significance (65%) and symptomatic l

108 Monoclonal gammopathy of renal significance (MGRS) defines disorder

109 Monoclonal gammopathy of renal significance (MGRS) is increasingly

110 The term monoclonal gammopathy of renal significance (MGRS) was introduced b

111 Recently, the term monoclonal gammopathy of renal significance (MGRS) was introduced t

112 Hematological diagnosis was monoclonal gammopathy of renal significance in 30 (60%), multiple m

113 Hematological diagnosis was monoclonal gammopathy of renal significance in 64% and symptomatic

114 We think the term monoclonal gammopathy of renal significance is most helpful to indi

115 bone marrow biopsy which revealed Monoclonal Gammopathy of renal significance, triggering a HUS and t

116 as determined in 63 patients with monoclonal gammopathy of uncertain significance (MGUS) and 198 pati

117 s of normal plasma cells (PCs) to monoclonal gammopathy of uncertain significance (MGUS) and multiple

118 human controls and patients with monoclonal gammopathy of uncertain significance expressed higher le

119 Aberrant demethylation in monoclonal gammopathy of uncertain significance occurred primarily

120 bjects representing premalignant (monoclonal gammopathy of uncertain significance), early, and advanc

121 CGH on 25 cases of MM, 4 cases of monoclonal gammopathy of uncertain significance, and 1 case of Wald

122 cal study in a person with advanced ALS, IgA gammopathy of unclear significance, and B lymphopenia, C

123 ent course of disease that mimics monoclonal gammopathy of undermined significance, whereas others ha

124 oma (SMM) bridges the gap between monoclonal gammopathy of undetermined significance (a mostly premal

125 with WM and 10 patients with IgM monoclonal gammopathy of undetermined significance (IgM MGUS).

126 Immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (IgM-MGUS) and a

127 58 patients with WM, 77 with IgM monoclonal gammopathy of undetermined significance (IgM-MGUS), 84 w

128 othelial cells from patients with monoclonal gammopathy of undetermined significance (MGECs) and endo

129 s from subjects with MM (n = 16), monoclonal gammopathy of undetermined significance (MGUS) (n = 6),

130 somes from multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS) and healt

131 4+ CD25+ T cells in patients with monoclonal gammopathy of undetermined significance (MGUS) and in pa

132 arly pathogenesis of premalignant monoclonal gammopathy of undetermined significance (MGUS) and malig

133 Monoclonal gammopathy of undetermined significance (MGUS) and multi

134 rrow specimens from patients with monoclonal gammopathy of undetermined significance (MGUS) and multi

135 ignant non-immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS) and multi

136 ly expressed in plasma cells from monoclonal gammopathy of undetermined significance (MGUS) and multi

137 eceded by the precursor states of monoclonal gammopathy of undetermined significance (MGUS) and smold

138 Monoclonal gammopathy of undetermined significance (MGUS) and smold

139 (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS) and smold

140 ant plasma cell dyscrasia such as monoclonal gammopathy of undetermined significance (MGUS) and smold

141 Patients with monoclonal gammopathy of undetermined significance (MGUS) are at in

142 Monoclonal gammopathy of undetermined significance (MGUS) can progr

143 ering of the precursor condition, monoclonal gammopathy of undetermined significance (MGUS) has been

144 lls in the blood of patients with monoclonal gammopathy of undetermined significance (MGUS) has been

145 r et al showed that patients with monoclonal gammopathy of undetermined significance (MGUS) have incr

146 e reported a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS) in Africa

147 Monoclonal gammopathy of undetermined significance (MGUS) is a comm

148 Monoclonal gammopathy of undetermined significance (MGUS) is a plas

149 Monoclonal gammopathy of undetermined significance (MGUS) is a prec

150 Monoclonal gammopathy of undetermined significance (MGUS) is a prem

151 Monoclonal gammopathy of undetermined significance (MGUS) is a prem

152 Monoclonal gammopathy of undetermined significance (MGUS) is an asy

153 Monoclonal gammopathy of undetermined significance (MGUS) is an asy

154 Monoclonal gammopathy of undetermined significance (MGUS) is an asy

155 Monoclonal gammopathy of undetermined significance (MGUS) is associ

156 Monoclonal gammopathy of undetermined significance (MGUS) is associ

157 Monoclonal gammopathy of undetermined significance (MGUS) is define

158 We examined whether monoclonal gammopathy of undetermined significance (MGUS) is increa

159 Monoclonal gammopathy of undetermined significance (MGUS) is presen

160 IgM monoclonal gammopathy of undetermined significance (MGUS) is the mo

161 Whether this dichotomy exists in monoclonal gammopathy of undetermined significance (MGUS) is uncert

162 The association of obesity with monoclonal gammopathy of undetermined significance (MGUS) is unknow

163 Monoclonal gammopathy of undetermined significance (MGUS) is, in ma

164 A monoclonal gammopathy of undetermined significance (MGUS) occurs in

165 to quantitate adverse outcomes of monoclonal gammopathy of undetermined significance (MGUS) of the im

166 pathy (AMG), classified as either monoclonal gammopathy of undetermined significance (MGUS) or asympt

167 Unlike monoclonal gammopathy of undetermined significance (MGUS) or non-Ho

168 At diagnosis, most patients had monoclonal gammopathy of undetermined significance (MGUS) or smolde

169 nditions recognized clinically as monoclonal gammopathy of undetermined significance (MGUS) or smolde

170 eceded by precursor states termed monoclonal gammopathy of undetermined significance (MGUS) or smolde

171 (MM) patients (n = 8740) and 5652 monoclonal gammopathy of undetermined significance (MGUS) patients

172 in 90% of immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS) patients.

173 Hypercalcemia in monoclonal gammopathy of undetermined significance (MGUS) presents

174 Monoclonal gammopathy of undetermined significance (MGUS) progresse

175 ith AL-amyloidosis secondary to a monoclonal gammopathy of undetermined significance (MGUS) referred

176 ation from immunoglobulin-M (IgM) monoclonal gammopathy of undetermined significance (MGUS) remain un

177 Monoclonal gammopathy of undetermined significance (MGUS) represent

178 patients is more consistent with monoclonal gammopathy of undetermined significance (MGUS) than with

179 study the risk of progression of monoclonal gammopathy of undetermined significance (MGUS) to lympho

180 y a role in the transformation of monoclonal gammopathy of undetermined significance (MGUS) to MM.

181 The transformation from monoclonal gammopathy of undetermined significance (MGUS) to multip

182 cogenic drivers of progression of monoclonal gammopathy of undetermined significance (MGUS) to multip

183 s that determine progression from monoclonal gammopathy of undetermined significance (MGUS) to multip

184 dering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) to multip

185 hat the clinical progression from monoclonal gammopathy of undetermined significance (MGUS) to multip

186 leading the transformation of the monoclonal gammopathy of undetermined significance (MGUS) to myelom

187 ple myeloma (MM) and premalignant monoclonal gammopathy of undetermined significance (MGUS) tumors: a

188 ate the outcomes of patients with monoclonal gammopathy of undetermined significance (MGUS) with COVI

189 untreated active myeloma, 14 had monoclonal gammopathy of undetermined significance (MGUS), 10 had d

190 Monoclonal gammopathy of undetermined significance (MGUS), a precur

191 om two out of eight patients with monoclonal gammopathy of undetermined significance (MGUS), a precur

192 re suggested to jointly influence monoclonal gammopathy of undetermined significance (MGUS), a precur

193 The prevalence of monoclonal gammopathy of undetermined significance (MGUS), a premal

194 detected in 5 of 5 patients with monoclonal gammopathy of undetermined significance (MGUS), an early

195 sed multiple myeloma (MM), 5 with monoclonal gammopathy of undetermined significance (MGUS), and 31 h

196 multiple myeloma, three cases of monoclonal gammopathy of undetermined significance (MGUS), and five

197 da immunoglobulin light chains in monoclonal gammopathy of undetermined significance (MGUS), as detec

198 ones of a subset of patients with monoclonal gammopathy of undetermined significance (MGUS), asymptom

199 ties to multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS), but its

200 tions have been identified in the monoclonal gammopathy of undetermined significance (MGUS), but thei

201 In 728 Swedish cases of monoclonal gammopathy of undetermined significance (MGUS), followed

202 l clone, referred to as secondary monoclonal gammopathy of undetermined significance (MGUS), have bee

203 Plasma cell dyscrasias, including monoclonal gammopathy of undetermined significance (MGUS), multiple

204 n plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS), smolderi

205 eloma is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS), which is

206 myeloma to a benign form known as monoclonal gammopathy of undetermined significance (MGUS), which re

207 e an increased fracture risk with monoclonal gammopathy of undetermined significance (MGUS).

208 from a premalignant stage called monoclonal gammopathy of undetermined significance (MGUS).

209 applicators to assess the risk of monoclonal gammopathy of undetermined significance (MGUS).

210 logy of multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS).

211 onoclonal gammopathies, including monoclonal gammopathy of undetermined significance (MGUS).

212 m a common benign PC tumor called Monoclonal Gammopathy of Undetermined Significance (MGUS).

213 le myeloma (MM) and its precursor monoclonal gammopathy of undetermined significance (MGUS).

214 ded by an asymptomatic condition, monoclonal gammopathy of undetermined significance (MGUS).

215 a premalignant condition known as monoclonal gammopathy of undetermined significance (MGUS).

216 preceded by the precursor state, monoclonal gammopathy of undetermined significance (MGUS).

217 myeloma and its precursor state, monoclonal gammopathy of undetermined significance (MGUS); however,

218 than 500 untreated patients with monoclonal gammopathy of undetermined significance (MGUS; n = 14),

219 s relatively common and occurs in monoclonal gammopathy of undetermined significance (MGUS; n=17), sm

220 l [CI], 1.31-17.86; P = .018) and monoclonal gammopathy of undetermined significance (OR, 5.94; 95% C

221 rrow in preneoplastic gammopathy (monoclonal gammopathy of undetermined significance [MGUS]).

222 acroglobulinemia [WM], 6 with IgM monoclonal gammopathy of undetermined significance [MGUS], and 5 no

223 ls (B cells, normal plasma cells, monoclonal gammopathy of undetermined significance [MGUS], presenta

224 They are seen rarely as a monoclonal gammopathy of undetermined significance and are present

225 ypic profiles between AL and both monoclonal gammopathy of undetermined significance and MM PCs.

226 te potential (CHIP), analogous to monoclonal gammopathy of undetermined significance and monoclonal B

227 luding asymptomatic states called monoclonal gammopathy of undetermined significance and smoldering m

228 precursor states of MM, including monoclonal gammopathy of undetermined significance and smoldering M

229 m precursor conditions, including monoclonal gammopathy of undetermined significance and smoldering m

230 oreover, analyses of samples from monoclonal gammopathy of undetermined significance and smouldering

231 Our goal was to develop a monoclonal gammopathy of undetermined significance and smouldering

232 one marrow involvement similar to monoclonal gammopathy of undetermined significance at diagnosis, th

233 criteria were newly diagnosed MM, monoclonal gammopathy of undetermined significance at high risk for

234 SMM is distinguished from monoclonal gammopathy of undetermined significance by a much higher

235 Monoclonal gammopathy of undetermined significance isotype; monoclo

236 healthy donors and patients with monoclonal gammopathy of undetermined significance or other plasma

237 ment cells in transformation from monoclonal gammopathy of undetermined significance or smoldering mu

238 s who were 18 years or older with monoclonal gammopathy of undetermined significance or smouldering m

239 matic precursor conditions-either monoclonal gammopathy of undetermined significance or smouldering m

240 rum adiponectin concentrations in monoclonal gammopathy of undetermined significance patients who sub

241 terials and Methods Patients with monoclonal gammopathy of undetermined significance prospectively un

242 nt disease stages, from 23.66% in monoclonal gammopathy of undetermined significance to 3.23% in MMs

243 d model of genetic evolution from monoclonal gammopathy of undetermined significance to MM.

244 n that parallels progression from monoclonal gammopathy of undetermined significance to MM.

245 An IgG kappa monoclonal gammopathy of undetermined significance was found.

246 Plasma cells in 10 patients with monoclonal gammopathy of undetermined significance were not stained

247 s can help identify patients with monoclonal gammopathy of undetermined significance who are developi

248 y be the presenting feature); and monoclonal gammopathy of undetermined significance with atypical cl

249 characteristics that evolves from monoclonal gammopathy of undetermined significance, a highly preval

250 S from neuropathy associated with monoclonal gammopathy of undetermined significance, additional crit

251 in amyloidosis, multiple myeloma, monoclonal gammopathy of undetermined significance, and non-parapro

252 Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clon

253 n from the non-malignant disorder monoclonal gammopathy of undetermined significance, are poorly unde

254 amyloidosis, multiple myeloma and monoclonal gammopathy of undetermined significance, immunoreactive

255 reexisting plasma cell disorders, monoclonal gammopathy of undetermined significance, or smoldering m

256 plasma cells from healthy donors, monoclonal gammopathy of undetermined significance, smoldering MM,

257 f paraproteinemia in a setting of monoclonal gammopathy of undetermined significance, smoldering plas

258 on to delineate the complexity of monoclonal gammopathy of undetermined significance, smouldering MM

259 in both multiple myeloma (MM) and monoclonal gammopathy of undetermined significance, suggesting that

260 tients with IgG/IgA (but not IgM) monoclonal gammopathy of undetermined significance, supporting a ro

261 MM, whereas nonprogressor SMM has monoclonal gammopathy of undetermined significance-like characteris

262 myeloproliferative disorder, and monoclonal gammopathy of undetermined significance.

263 ive premalignant condition termed monoclonal gammopathy of undetermined significance.

264 eloma cells, even in asymptomatic monoclonal gammopathy of undetermined significance.

265 ave shown limited efficacy in IgM monoclonal gammopathy of undetermined significance.

266 rease in MM cell proliferation in monoclonal gammopathy of undetermined significance/smoldering MM co

267 Monoclonal gammopathy of unknown significance (MGUS) and smoldering

268 tion of SOCS1 and SYK; (5) MM and monoclonal gammopathy of unknown significance (MGUS) had infrequent

269 ients with MM, chronic leukemias, monoclonal gammopathy of unknown significance (MGUS), PBC, and heal

270 the precursor malignant condition monoclonal gammopathy of unknown significance (MGUS).

271 e myeloma (MM) and its precursor, monoclonal gammopathy of unknown significance (MGUS).

272 Although the high prevalence of a monoclonal gammopathy of unknown significance in SCLS suggests a pa

273 the limited plasma cell disorder monoclonal gammopathy of unknown significance or in nonmyeloma hema

274 patients with multiple myeloma or monoclonal gammopathy of unknown significance sequentially underwen

275 5 with smoldering MM, and 4 with monoclonal gammopathy of unknown significance) and 20 individuals w

276 a, marginal-zone lymphoma, or IgM monoclonal gammopathy of unknown significance.

277 T-cell populations, analogous to monoclonal gammopathy of unknown significance.

278 that the patient had unrecognized monoclonal gammopathy of unknown significance.

279 s with indolent smoldering MM and monoclonal gammopathy of unknown significance.

280 s through a premalignant state of monoclonal gammopathy of unknown significance; however, the molecul

281 ere at high risk for developing a monoclonal gammopathy on the basis of Black race or a family histor

282 onstellation of lambda-restricted monoclonal gammopathy, plasma cell rimming around lymphoid aggregat

283 Polyclonal gammopathy pretransplant is common with 17% of all patie

284 Paraproteinemia relates to monoclonal gammopathy-producing pathologic antibodies with serous m

285 unexpected low rate of detectable monoclonal gammopathy, questioning the reality of an underlying clo

286 mmune GN, autoinflammatory GN and monoclonal gammopathy-related GN.

287 d by the International Kidney and Monoclonal Gammopathy Research Group (IKMG) in 2012.

288 xenografts from patients with preneoplastic gammopathy showed progressive growth, suggesting that th

289 Its differentiation from other IgM-producing gammopathies such as Waldenstrom macroglobulinemia (WM)

290 tiple myeloma (MM) are 2 distinct monoclonal gammopathies that involve the same cellular compartment:

291 RS) was introduced to distinguish monoclonal gammopathies that result in the development of kidney di

292 s, a form of renal involvement by monoclonal gammopathy that mimics immune-complex glomerulonephritis

293 iple myeloma is the most frequent monoclonal gammopathy to involve the kidney; however, a growing num

294 ge renal disease and known benign monoclonal gammopathy underwent kidney transplantation at Westchest

295 nt somatic mutation in benign monoclonal IgM gammopathy, Waldenstrom's macroglobulinemia, and diffuse

296 The mean age of IBM patients with gammopathy was 60.6 years (range, 35-77 years), compared

297 Monoclonal gammopathy was of IgG type in 47 (94%) patients.

298 All monoclonal gammopathies were associated with an increased likelihoo

299 ge, is frequently associated with monoclonal gammopathies, which often recognize various muscle compo

300 focused on defining differences between IgM gammopathies (WM/IgM-MGUS) compared with controls, and s